SCHEMBL1460104

SCHEMBL1460104

Cc1cc(S(=O)(=O)N(C)C)ccc1B(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
THRB P10828 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 1/20 0.41
VCAM1 P19320 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SERPINE1 P05121 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954218 1.00 ALDH1A1 (0.43) ALDH1A1MAPTNPSR1THRBSMN1; SMN2
SCHEMBL12537974 0.86 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1THRBSMN1; SMN2
SCHEMBL29956045 0.81 SMN1; SMN2 (0.51) ALDH1A1MAPTNPSR1SMN1; SMN2HTT
SCHEMBL16600125 0.81 SMN1; SMN2 (0.51) ALDH1A1MAPTNPSR1SMN1; SMN2HTT
SCHEMBL2634586 0.79 ENPP2 (0.53) ALDH1A1SMN1; SMN2LMNAPKM
SCHEMBL19255842 0.79 LMNA (0.57) ALDH1A1MAPTNPSR1THRBSMN1; SMN2
SCHEMBL30633354 0.78 CA2 (0.47) MAPTHTTLMNAGAARAB9A
SCHEMBL15751431 0.78 CA2 (0.47) MAPTHTTLMNAGAARAB9A
SCHEMBL172720 0.78 ESR1 (0.56) ALDH1A1MAPTNPSR1THRBSMN1; SMN2
SCHEMBL1459011 0.77 TRPV4 (0.42) ALDH1A1MAPTSMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834521-B2 Choline kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160244437-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-25 US disclosed
US-20160237044-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
EP-3049394-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA Bayer Pharma Aktiengesellschaft (DE) 2016-08-03 EP disclosed
EP-3049406-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES AND USE THEREOF TO TREAT THROMBOTIC/THROMBOEMBOLIC DISEASES Bayer Pharma Aktiengesellschaft (DE) 2016-08-03 EP disclosed
US-20160024024-A1 Novel Choline Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2016-01-28 US disclosed
EP-2968358-A1 NOVEL CHOLINE KINASE INHIBITORS ARIAD Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 US disclosed
WO-2015044167-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-04-02 WO disclosed
WO-2015044170-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES AND USE THEREOF TO TREAT THROMBOTIC/THROMBOEMBOLIC DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-04-02 WO disclosed
EP-2738172-A1 New bicyclic compounds as crac channel modulators Almirall, S.A. (ES) 2014-06-04 EP disclosed
WO-2013092463-A1 4-AZAINDOLE INHIBITORS OF CRAC F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 WO disclosed
WO-2013092444-A1 DIAZAINDOLE INHIBITORS OF CRAC F. HOFFMANN-LA ROCHE AG (CH) 2013-06-27 WO disclosed
US-20130158066-A1 4-AZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20130158040-A1 DIAZAINDOLE INHIBITORS OF CRAC HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors AMGEN INC. (US) 2013-06-13 US disclosed
WO-2013086229-A1 BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2013-06-13 WO disclosed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024024-A1 Novel Choline Kinase Inhibitors CHKA, CHKB, CEPT1 ALDH1A1 2140/4885MAPT 1174/4885NPSR1 3067/4885
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E ALDH1A1 1801/4885MAPT 2068/4885NPSR1 322/4885
US-20130158040-A1 DIAZAINDOLE INHIBITORS OF CRAC ORAI2, ORAI1, RYR2 ALDH1A1 1480/4885MAPT 4260/4885NPSR1 2074/4885
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors SCN1A, SCN1B, CACNA1B ALDH1A1 795/4885MAPT 3559/4885NPSR1 878/4885
US-20130158066-A1 4-AZAINDOLE INHIBITORS OF CRAC ORAI1, CACNA1I, RYR2 ALDH1A1 1339/4885MAPT 4107/4885NPSR1 2031/4885
US-20160237044-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, AADAT, TTR ALDH1A1 1733/4885MAPT 2437/4885NPSR1 1547/4885
US-20160244437-A1 SUBSTITUTED PHENYLALANINE DERIVATIVES PAH, PEPD, AADAT ALDH1A1 1067/4885MAPT 2910/4885NPSR1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.